• From Medicine to Moderna: How Physicians Can Break Into Biotech with Dr. Francois Nader

  • Oct 31 2024
  • Length: 47 mins
  • Podcast

From Medicine to Moderna: How Physicians Can Break Into Biotech with Dr. Francois Nader

  • Summary

  • In this episode of the "Pemba On Demand" podcast, host Dr. Norman A. Chapin celebrates the one-year anniversary by interviewing Dr. Francois Nader, an alumnus of the Physician Executive MBA program at the University of Tennessee. Dr. Nader shares his journey from medicine to the biotech industry, emphasizing the evolving role of physicians in life sciences. He discusses opportunities for physicians in biotech, the appeal of continuous learning, and the complexities of drug development and pricing. The episode provides valuable insights for physicians considering a transition into the biotech sector, highlighting the industry's dynamic nature and potential for innovation.

    Show Highlights:
    • Transition of physicians from clinical practice to the biotech industry.
    • Opportunities for physicians in biotech and life sciences.
    • Evolving roles of physicians in drug development and patient care.
    • Insights into the drug development process and its complexities.
    • Discussion on drug pricing and its implications for healthcare.
    • Importance of continuous learning and adaptation in the biotech sector.
    • Skills and specialties in demand within the biotech industry.
    • The impact of the COVID-19 pandemic on biotech innovation and awareness.
    • Value of an MBA for physicians transitioning to industry roles.
    • Challenges faced by physicians when moving from clinical to industry environments.

    Links and Resources:

    • Physician Executive MBA at the University of Tennessee
    • Francois Nader, MD, MBA

    Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about From Medicine to Moderna: How Physicians Can Break Into Biotech with Dr. Francois Nader

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.